The historical rank and industry rank for Beta Drugs's OCF Margin % or its related term are showing as below:
NSE:BETA'
s OCF Margin % Range Over the Past 10 Years
Min: 0.17 Med: 10.38 Max: 33.83
Current: 20.57
During the past 13 years, the highest OCF Margin % of Beta Drugs was 33.83%. The lowest was 0.17%. And the median was 10.38%.
NSE:BETA's OCF Margin % is ranked better than 78.31% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.94
vs NSE:BETA: 20.57
Beta Drugs OCF Margin % Related Terms
Beta Drugs OCF Margin % Historical Data
* Premium members only.
The historical data trend for Beta Drugs's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Beta Drugs's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Beta Drugs and its competitors. Over the past decade, Beta Drugs' OCF Margin % has ranged from 0.17 to 33.83. According to the industry distribution chart, Beta Drugs ranks #208 out of 959 companies in the Drug Manufacturers industry, placing it in the top 21.7%.
Is Beta Drugs' OCF Margin % too high?
Beta Drugs' current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 0.17 to a high of 33.83. Based on the distribution chart, Beta Drugs ranks #208 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' OCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #208 out of 959 companies for OCF Margin %. This places Beta Drugs in the top 22% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.94. Historically, Beta Drugs' own OCF Margin % has ranged from 0.17 to 33.83 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.94, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,960.95, compared to a current price of ₹2,096.60 — trading 6.9% above its estimated fair value. The current OCF Margin % is 0.00%. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,096.60 is trading 6.9% above its estimated GF Value™ of ₹1,960.95.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
OCF Margin %: 0.00%
GF Value™: ₹1,960.95 vs. price of ₹2,096.60 (6.9% above fair value)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score
Get the complete analysis for NSE:BETA
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
